Cambridge, United Kingdom
Vernalis, founded in 1997, is a UK-based company operating at the forefront of the Biotechnology and Pharmaceutical industries. With a commitment to advancing drug discovery, their slogan encapsulates their mission: "We develop and apply fragment and structure-based methods to solve problems in drug discovery."
The company excels in developing cell-active lead compounds and generating development candidates targeting key areas such as oncology, neurodegeneration, anti-infectives, and inflammation. Situated at their state-of-the-art laboratories on Granta Park, Cambridge, they capitalize on a synthesis of fragment-based techniques, cutting-edge structural biology, biophysics, and molecular modelling, supported by extensive medicinal chemistry expertise. This unique blend enables Vernalis to advance projects from target identification to clinical candidate selection.
Their collaboration-driven model includes partnerships with leading pharmaceutical entities like Servier, Daiichi Sankyo, Lundbeck, and Asahi Kasei Pharma. The firm's last recorded investment was a Venture Round investment on 15 January 2007 from Thuja Capital, highlighting the potential for further financing opportunities to scale their innovative research endeavors.
